Phathom Pharmaceuticals (NASDAQ: PHAT) net income
Phathom Pharmaceuticals reported a net loss of $221.2m for fiscal 2025; in fiscal 2024 it reported a net loss of $334.3m. Earnings per share were −$3.03.
Phathom Pharmaceuticals's best year of the last 8 was fiscal 2018. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$221.2m | — | −126.3% | −$3.03 |
| 2024 | −$334.3m | — | −605.1% | −$5.29 |
| 2023 | −$201.6m | — | −29,558.9% | −$3.93 |
| 2022 | −$197.7m | — | — | −$5.05 |
| 2021 | −$143.9m | — | — | −$3.89 |
| 2020 | −$129.1m | — | — | — |
| 2019 | −$255.1m | — | — | — |
| 2018 | −$1.3m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Phathom Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Phathom Pharmaceuticals ranks 422nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Phathom Pharmaceuticals, −126.3%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 420th | Cullinan Therapeutics | −$219.9m | — |
| 421st | Vanda Pharmaceuticals | −$220.5m | −102.0% |
| 422nd | Phathom Pharmaceuticals | −$221.2m | −126.3% |
| 423rd | Rocket Pharmaceuticals | −$223.1m | — |
| 424th | OPKO Health | −$225.7m | −37.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Phathom Pharmaceuticals
- How much did Phathom Pharmaceuticals earn in fiscal 2025?
- Phathom Pharmaceuticals reported a net loss of $221.2m for fiscal 2025. In fiscal 2024 it reported a net loss of $334.3m.
- What are the earnings per share of Phathom Pharmaceuticals?
- They were −$3.03 in fiscal 2025, compared with −$5.29 in fiscal 2024.
- Where does Phathom Pharmaceuticals rank in its sector by net income?
- It ranks 422nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Phathom Pharmaceuticals come from?
- From the annual report (Form 10-K) that Phathom Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Phathom Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Phathom Pharmaceuticals: the Phathom Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.